All In Biotech

Drug Trial Radar · NCT06716216

A Study of BGM0504 in Participants With Type 2 Diabetes

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin and/or Sulfonylureas in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 553 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

553

Actual

Start

Jan 13, 2025

Primary completion

Aug 25, 2026

Study completion Aug 25, 2026

Sponsor

Sponsor type
Industry
Collaborators
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • Drug: 5 mg BGM0504 Administered SCDrug

    Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

  • Drug:10 mg BGM0504 Administered SCDrug

    Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

  • Drug: Semaglutide Administered SCDrug

    Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Week 0 to Week 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.